Abstract
A novel series of ten N-(aryl)-2-(2-methyl-1H-imidazol-1-yl)acetamides (5a-j) were synthesized by reacting 2- methylimidazole (4) with the corresponding ω- chloroacetanilides (3a-j) in Dimethly Formamide and potassium carbonate. The compounds have been characterized on the basis of elemental analysis and spectral data. All the synthesized compounds were screened for their anticonvulsant activity. Among the compounds subjected to anticonvulsant activity, compounds 5a, 5b, 5d, 5f, 5g, 5h, 5i and 5j, at a dose of 100mg/kg body weight i.p. showed significant anticonvulsant activity (p<0.01) as they delayed the onset of convulsions. The compounds 5a, 5d, 5h, 5i and 5j also decreased the duration of seizures significantly (p<0.01 and P<0.05) and the results were comparable to the diazepam treated group. Compound 5g is the most active molecule as; it increased the onset of convulsion time to nearly two fold and comparable duration of action to that of diazepam.
Keywords: 2-Methylimidazole, ω- Chloroacetanilides, Acetamides, Anticonvulsant
Letters in Drug Design & Discovery
Title:Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Volume: 9 Issue: 4
Author(s): Rahul Mishra, Swastika Ganguly, Kalyan Kumar Sethi, Papiya Mitra Mazumder
Affiliation:
Keywords: 2-Methylimidazole, ω- Chloroacetanilides, Acetamides, Anticonvulsant
Abstract: A novel series of ten N-(aryl)-2-(2-methyl-1H-imidazol-1-yl)acetamides (5a-j) were synthesized by reacting 2- methylimidazole (4) with the corresponding ω- chloroacetanilides (3a-j) in Dimethly Formamide and potassium carbonate. The compounds have been characterized on the basis of elemental analysis and spectral data. All the synthesized compounds were screened for their anticonvulsant activity. Among the compounds subjected to anticonvulsant activity, compounds 5a, 5b, 5d, 5f, 5g, 5h, 5i and 5j, at a dose of 100mg/kg body weight i.p. showed significant anticonvulsant activity (p<0.01) as they delayed the onset of convulsions. The compounds 5a, 5d, 5h, 5i and 5j also decreased the duration of seizures significantly (p<0.01 and P<0.05) and the results were comparable to the diazepam treated group. Compound 5g is the most active molecule as; it increased the onset of convulsion time to nearly two fold and comparable duration of action to that of diazepam.
Export Options
About this article
Cite this article as:
Rahul Mishra, Swastika Ganguly, Kalyan Kumar Sethi, Papiya Mitra Mazumder , Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799860015
DOI https://dx.doi.org/10.2174/157018012799860015 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Animal Models of Narcolepsy
CNS & Neurological Disorders - Drug Targets Drug Repositioning: Antimalarial Activities of GABA Analogs in Mice Infected with <i>Plasmodium berghei</i>
Central Nervous System Agents in Medicinal Chemistry Children with Medical Complexity: Forwarding a Policy Agenda
Current Pediatric Reviews Pharmacological Characterisation and Modulation of Neuroplasticity in Humans
Current Neuropharmacology N-Valproyl-L-Tryptophan for CNS-Targeting: Synthesis, Characterization and Efficacy In Vitro Studies of a New Potential Antiepileptic Drug
Medicinal Chemistry Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry Pharmacogenetics of Opioids for the Treatment of Acute Maternal Pain During Pregnancy and Lactation
Current Drug Metabolism Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry Cytotoxicity and Anti-proliferative Properties of Heterocyclic Compounds Derived from Progesterone
Anti-Cancer Agents in Medicinal Chemistry Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design